慢性肾功能不全与肺动脉压关系及其相关因素研究

摘要
图/表
参考文献
相关文章 (2)

全文: PDF (1968 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的：探讨慢性肾功能不全患者其肺动脉压的变化,并分析慢性肾脏病（chronic kidney disease,CKD）进展的危险因素。方法：回顾性分析联勤保障部队第九二一医院2021年1月―2022年12月间就诊的CKD患者,分析在不同估算肾小球滤过率（estimated glomerular filtration rate,eGFR）下肺动脉压的变化特点,同时比较各因素对慢性肾功能不全患者的影响。结果：随着CKD分期增高,肺动脉压呈逐步增长趋势。在119名CKD患者中合并有肺动脉高压的有18例,其中1~2期 0例,3期4例,4期6例,5期8例。同时随着肾小球滤过率（eGFR）下降,患者血红蛋白（Hb）及血小板（PLT）下降,D-二聚体升高。结论：肺动脉压与肾小球滤过率（eGFR）呈反比关系,即当肾小球滤过率（eGFR）下降时,心血管风险随之增加,且早期CKD患者积极治疗贫血,降低肺动脉压可减缓肾脏疾病进展。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	袁源
	王倩芸
	刘春慧
	杨海蓉
	王湘川

关键词 ：慢性肾脏疾病, 肺动脉压, 肾小球滤过率, 贫血

Abstract：Objective To investigate the relationship between glomerular filtration rate and pulmonary artery pressure, and to analyze the risk factors for CKD progression. Methods The patients with CKD who visited the 921st Hospital of the Joint Logistics Support Force between January 2019 and December 2021 were retrospectively analyzed, and the variation characteristics of pulmonary artery pressure under different glomerular filtration rate (eGFR) were analyzed, and the effects of various factors on patients with chronic renal insufficiency were compared. Results As the CKD staging increased, the pulmonary artery pressure showed a gradual increase trend. Among the 119 patients with CKD, there were 18 cases with combined pulmonary hypertension, 0 cases including 1-2 stage, 4 cases in stage 3, 6 cases in stage 4, and 8 cases in stage 5. At the same time, with the decrease of eGFR (glomerular filtration rates), the patient's hemoglobin (Hb) and platelet (PLT) decreased, and the D2 polymer increased. Conclusion There is an inverse relationship between pulmonary artery pressure and eGFR, that is, when eGFR decreases, cardiovascular risk increases, and early CKD patients actively treat anemia, reducing pulmonary artery pressure can aueviate the progression of kidney disease.

Key words： chronic kidney disease pulmonary artery pressure glomerular filtration rate anemia

收稿日期: 2023-03-14

中图分类号:

R692.6

基金资助:湖南省残疾人联合会康复医疗（2021XK0324）

通讯作者: 王湘川,Email：634263633@qq.com

引用本文:

袁源, 王倩芸, 刘春慧, 杨海蓉, 王湘川. 慢性肾功能不全与肺动脉压关系及其相关因素研究[J]. 湖南师范大学学报(医学版), 2023, 20(3): 107-109. YUAN Yuan, WANG Qianyun, LIU Chunhui, YANG Hairong, WANG Xiangchuan. The relationship between chronic renal insufficiency and pulmonary artery pressure and its related factors. HuNan ShiFan DaXue XueBao(YiXueBan), 2023, 20(3): 107-109.

链接本文:

http://yxb.hunnu.edu.cn/CN/ 或 http://yxb.hunnu.edu.cn/CN/Y2023/V20/I3/107

[1] Bikbov B, Purcell C, Levey A S, et al.Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2020, 395(10225): 709-733.
[2] Thomas B, Matsushita K, Abate K H, et al.Global Cardiovascular and Renal Outcomes of Reduced GFR[J]. J Am Soc Nephrol, 2017, 28(7): 2167-2179.
[3] Thompson S, James M, Wiebe N, et al.Cause of Death in Patients with Reduced Kidney Function[J]. J Am Soc Nephrol, 2015, 26(10): 2504-2511.
[4] Webster A C, Nagler E V, Morton R L, et al.Chronic kidney disease[J]. Lancet, 2017, 389(10075): 1238-1252.
[5] 吴积新. 超声心动图对肺动脉高压的诊断价值[J]. 临床超声医学杂志, 2014, 16(04): 274-276.
[6] Galiè N, Humbert M, Vachiery JL, , et al.2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)[J]. European Heart Journal,2016,37(1):67-119.
[7] 王倩芸, 王湘川, 罗淑, 等. 湖南省某高校新生慢性肾脏病流行病学调查[J]. 中南大学学报 (医学版) , 2020, 45(08): 935-940.
[8] Martinez R, Lloyd-sherlock P, Soliz P, et al. Trends in premature avertable mortality from non-communicable diseases for 195 countries and territories, 1990-2017: a population-based study[J]. Lancet Global Health, 2020, 8(4): E511-E523.
[9] Jankowski J, Floege J, Fliser D, et al.Cardiovascular Disease in Chronic Kidney Disease Pathophysiological Insights and Therapeutic Options[J]. Circulation, 2021, 143(11): 1157-1172.
[10] Sharain K, Hoppensteadt D, Bansal V, et al.Progressive Increase of Inflammatory Biomarkers in Chronic Kidney Disease and End-Stage Renal Disease[J]. Clin Appl Thromb Hemost, 2013, 19(3): 303-308.
[11] Navaneethan S D, Yan J, Deswal A.Classification of Pulmonary Hypertension in CKD[J]. Am J Kidney Dis, 2020, 75(5): 690-692.
[12] Djudjaj S, Boor P.Cellular and molecular mechanisms of kidney fibrosis[J]. Mol Aspects Med, 2019, 65: 16-36.
[13] Ruiz-ortega M, Rayego-mateos S, Lamas S, et al. Targeting the progression of chronic kidney disease[J]. Nat Rev Nephrol, 2020, 16(5): 269-288.
[14] Saritas T, Floege J.Retarding progression of chronic kidney disease[J]. Innere Medizin (Heidelberg, Germany), 2023, 64(3): 240-246.
[15] Inker LA, Grams ME, Levey AS, et al.Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium[J]. Am J Kidney Dis, 2019, 73(2): 206-217.
[16] Brinkkoetter P T, Ising C, Benzing T.The role of the podocyte in albumin filtration[J]. Nat Rev Nephrol, 2013, 9(6): 328-336.
[17] Sun H, Li H, Yan J, et al.Loss of CLDN5 in podocytes deregulates WIF1 to activate WNT signaling and contributes to kidney disease[J]. Nat Commun, 2022, 13(1): 1600.
[18] Farrington D K, Sang Y, Grams M E, et al.Anemia Prevalence, Type, and Associated Risks in a Cohort of 5.0 Million Insured Patients in the United States by Level of Kidney Function[J]. Am J Kidney Dis, 2023, 81(2): 201-209.
[19] Vestergaard S V, Heide-jorgensen U, Van haalen H, et al. Risk of Anemia in Patients with Newly Identified Chronic Kidney Disease - A Population-Based Cohort Study[J]. Clinical Epidemiology, 2020, 12: 953-962.
[20] Olesen J B, Lip G Y H, Kamper A-L, et al. Stroke and Bleeding in Atrial Fibrillation with Chronic Kidney Disease[J]. N Engl J Med, 2012, 367(7): 625-635.
[21] Palmer SC, Di Micco L, Razavian M, et al.Effects of Antiplatelet Therapy on Mortality and Cardiovascular and Bleeding Outcomes in Persons With Chronic Kidney Disease : a systematic review and meta-analysis[J]. Ann Intern Med, 2012, 156(6): 445-459.
[22] Drawz P E, Beddhu S, Bignall O N R, et al. KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD[J]. Am J Kidney Dis, 2022, 79(3): 311-327.
[23] Chen T K, Knicely D H, Grams M E.Chronic Kidney Disease Diagnosis and Management: A Review[J]. JAMA, 2019, 322(13): 1294-1304.